Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is characterized by its predominant biliary excretion, making it unique among DPP-4 inhibitors as its clearance is not significantly reliant on renal function.
## Primary Indications
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM).
## Adult Dosing
5 mg orally once daily.
## Pediatric Dosing
Safety and efficacy have not been established in pediatric patients (<18 years). Use is not recommended.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required; safe for use in patients with severe renal impairment and end-stage renal disease.
* **Hepatic Impairment:** No dose adjustment required.
## Contraindications
* History of a serious hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
* Type 1 diabetes or diabetic ketoacidosis.
## Adverse Effects
* **Common:** Nasopharyngitis.
* **Serious:** Acute pancreatitis (rare), hypersensitivity reactions (urticaria, angioedema), severe and disabling arthralgia, and bullous pemphigoid.
* **Hypoglycemia:** Risk is low when used as monotherapy or with metformin; risk increases when used with insulin or insulin secretagogues (e.g., sulfonylureas).
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., rifampin):** May decrease linagliptin efficacy. If required, consider increasing monitoring or using an alternative agent if glycemic control deteriorates.
* **Insulin/Sulfonylureas:** May increase the risk of hypoglycemia. Consider dose reduction of the secretagogue or insulin.
## Monitoring
* HbA1c (typically every 3–6 months).
* Blood glucose monitoring as clinically indicated.
* Monitor for signs/symptoms of pancreatitis (persistent, severe abdominal pain).
* Monitor for skin blisters or erosions (investigate for bullous pemphigoid).
## Clinical Pearls
* Linagliptin is the only DPP-4 inhibitor that does not require renal dose adjustment.
* Can be taken with or without food.
* If a dose is missed, take as soon as remembered, but do not take two doses on the same day.
* Patients should be counseled on the symptoms of pancreatitis and advised to discontinue the medication and seek medical attention if symptoms occur.
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Clinical guidelines and prescribing information change frequently. Always verify the most current prescribing information via the manufacturer’s package insert or official institutional formularies before prescribing or administering medication.
